Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients

Camus Nimmo; James Millard; Kayleen Brien; Sashen Moodley; Lucy van Dorp; Keeren Lutchminarain; Allison Wolf; Alison D Grant; Francois Balloux; Alexander S Pym; Nesri Padayatchi; Max O'Donnell

doi:10.1183/13993003.02383-2019

Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients

Eur Respir J. 2020 Jun 4;55(6):1902383. doi: 10.1183/13993003.02383-2019. Print 2020 Jun.

Authors

Camus Nimmo^{1

2

3}, James Millard^{3

4

5}, Kayleen Brien³, Sashen Moodley³, Lucy van Dorp², Keeren Lutchminarain⁶, Allison Wolf⁷, Alison D Grant^{3

8}, Francois Balloux², Alexander S Pym³, Nesri Padayatchi⁹, Max O'Donnell^{10

11}

Affiliations

¹ Division of Infection and Immunity, University College London, London, UK.
² UCL Genetics Institute, University College London, London, UK.
³ Africa Health Research Institute, Durban, South Africa.
⁴ Wellcome Trust Liverpool Glasgow Centre for Global Health Research, Liverpool, UK.
⁵ Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.
⁶ National Health Laboratory Service, Durban, South Africa.
⁷ Dept of Medicine, Columbia University Medical Center, New York, NY, USA.
⁸ TB Centre, London School of Hygiene and Tropical Medicine, London, UK.
⁹ CAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
¹⁰ CAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa mo2130@cumc.columbia.edu.
¹¹ Dept of Medicine and Epidemiology, Columbia University Medical Center, New York, NY, USA.

Abstract

Genetic mutations linked to bedaquiline resistance were found before starting treatment and acquired during treatment in patients with drug-resistant TB and HIV in KwaZulu-Natal, South Africa. Routine bedaquiline resistance testing needs to be accelerated. http://bit.ly/2vnL4VY

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antitubercular Agents / therapeutic use
Coinfection* / drug therapy
Diarylquinolines / therapeutic use
HIV Infections* / complications
HIV Infections* / drug therapy
Humans
Mycobacterium tuberculosis*
Tuberculosis, Multidrug-Resistant* / complications
Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

Antitubercular Agents
Diarylquinolines
bedaquiline

Abstract

Publication types

MeSH terms

Substances

Grants and funding